(S)-N-(2-hydroxy-1-phenylethyl)isobutyramide | 1175639-40-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-(2-hydroxy-1-phenylethyl)isobutyramide
• 英文别名: N-[(1S)-2-hydroxy-1-phenylethyl]-2-methylpropanamide
• CAS: 1175639-40-3
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: KTMMWNYQBWCMKP-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-N-(2-hydroxy-1-phenylethyl)isobutyramide 在 4-二甲氨基吡啶 、 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以88%的产率得到(S)-2-isopropyl-4-phenyl-4,5-dihydrooxazole
  参考文献：
  名称：

  Chiral dinuclear phthalazine bridged bisoxazoline ligands: synthesis and application in enantioselective Cu-catalyzed conjugate addition of ZnEt2 to enones

  摘要：

  A new class of chiral dinuclear ligands with phthalazine bridged bisoxazoline scaffold was designed and prepared in convenient synthetic routes. H-1 NMR analysis showed that this class of ligands could coordinate with two metal ions, either same or different. These ligands afforded good to excellent yields and enantioselectivities in Cu-catalyzed conjugate addition of ZnEt2 to enones. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.02.098
• 作为产物：
  描述：

  L-苯甘氨醇 、 异丁酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以84%的产率得到(S)-N-(2-hydroxy-1-phenylethyl)isobutyramide
  参考文献：
  名称：

  Chiral dinuclear phthalazine bridged bisoxazoline ligands: synthesis and application in enantioselective Cu-catalyzed conjugate addition of ZnEt2 to enones

  摘要：

  A new class of chiral dinuclear ligands with phthalazine bridged bisoxazoline scaffold was designed and prepared in convenient synthetic routes. H-1 NMR analysis showed that this class of ligands could coordinate with two metal ions, either same or different. These ligands afforded good to excellent yields and enantioselectivities in Cu-catalyzed conjugate addition of ZnEt2 to enones. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.02.098

文献信息

• Heterocyclic inhibitors of ERK2 and uses thereof
  申请人：Cao Jingrong

  公开号：US20070265263A1

  公开（公告）日：2007-11-15

  Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z 1 and Z 2 are each independently nitrogen or CH and Ring A, T m R 1 , QR 2 , U n R 3 , and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

  本文介绍了一些具有下列式的蛋白激酶抑制剂的化合物： 其中Z1和Z2各自独立地为氮或CH，环A、TmR1、QR2、UnR3和Sp如说明书所述。这些化合物特别适用于抑制ERK2并治疗哺乳动物中由蛋白激酶抑制剂缓解的疾病，特别是癌症、炎症性疾病、再狭窄、糖尿病和心血管疾病等疾病。
• NOVEL JNK INHIBITORS
  申请人：Reddy Panduranga Adulla P.

  公开号：US20100298314A1

  公开（公告）日：2010-11-25

  Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.

  本发明涉及代替的咪唑[1,2-a]吡啶，咪唑[1,2-a]吡嗪，咪唑[1,2-c]嘧啶和咪唑[1,2-d]三嗪化合物，其化学式为：（1.0）。本发明还涉及使用化合物1.0治疗JNK1和ERK介导的疾病的方法。
• US7183307B2
  申请人：——

  公开号：US7183307B2

  公开（公告）日：2007-02-27
• US7253187B2
  申请人：——

  公开号：US7253187B2

  公开（公告）日：2007-08-07
• US7279476B2
  申请人：——

  公开号：US7279476B2

  公开（公告）日：2007-10-09